Novartis - Recruiting 18 years or older. - Open, Multi-centre, Non-interventional, Observational Study to Characterize the Impact That GI Complaints Have on Patient-reported Outcomes in Patients Who Have Had a Renal Transplant. Patients Will be Evaluated at Visit 1 and Then Again After 4 (+2) Weeks (Visit 2).
Genentech - Recruiting 18 years or older. - A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of RG7667 for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients.
East Carolina University - Recruiting 18 years to 75 years. - An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific HLA Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients.
Baylor Research Institute - Recruiting 18 years or older. - Quantitative Evaluation of Liver and Kidney Disease With Liver and Kidney Elastography Measurements in Liver Transplant Recipients Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years. - Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pfizer - Recruiting 18 years to 70 years. - A Phase 2, Multicenter, Open-Label, Active Comparator-Controlled, Extension Trial To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 In Renal Allograft Recipients.
Pfizer - Recruiting 18 years to 70 years. - A Multicenter, Phase 2, Open-Label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-Term Safety And Efficacy Of CP-690,550 Versus Tacrolimus, When Co-Administered With Mycophenolate Mofetil In Renal Allograft Recipients.
Novartis - Recruiting 18 years or older. - 12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certicanr Based Regimen Either in Combination With Cyclosporin A or Tacrolimus.
University of Colorado, Denver - Recruiting 18 years to 70 years. - Differentiating Sirolimus and Everolimus in Combination With Calcineurin Inhibitors in Long-term Maintenance of Kidney Transplant Patients - The Effects on Vascular Endothelial and Kidney Function. The DESIRE Study..
Massachusetts General Hospital - Recruiting 18 years to 70 years. - Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Hoffmann-La Roche - Recruiting 18 years or older. - Prospective, Open-label, Non-interventional Study for the Follow-up of Renal Function in de Novo Kidney Transplant Patients Treated With Immunosuppressive Therapy Containing CellCept in Routine Clinical Practice (ORANGE Study).
Astellas Pharma Inc - Recruiting 2 years to 17 years. - A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose-Titration Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisolr) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia.
Bristol-Myers Squibb - Recruiting 6 years to 17 years. - A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant.
Assistance Publique - Hpitaux de Paris - Recruiting 18 years to 75 years. - Prospective Double Blind Multicentre Randomized Trial of Vitamine D Estimating the Profit of a Treatment by Vitamin D3 at the Dose of 100000 UI by Comparison With a Treatment in the Dose of 12 000 UI at Renal Transplanted Patients.
Helsinki University Central Hospital - Recruiting 18 years to 70 years. - Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients.
Drexel University - Recruiting 18 years to 75 years. - One-year Exploratory Study to Evaluate the Safety of Partial Replacement of CNI With Chronic Administration of Simulect in de Novo Normal-risk Kidney Transplant Recipients Treated With MPA.
Medstar Research Institute - Recruiting 9 years to 17 years. - Immunogenicity Of A Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, And 18) L1 Virus-Like Particle Vaccine In Male And Female Adolescent Transplant Recipients..